Changzhou No.2 People's Hospital
🇨🇳China
Clinical Trials
10
Active:0
Completed:1
Trial Phases
4 Phases
Early Phase 1:2
Phase 1:2
Phase 2:4
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (44.4%)Early Phase 1
2 (22.2%)Phase 1
2 (22.2%)Not Applicable
1 (11.1%)UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
Phase 1
Not yet recruiting
- Conditions
- Systemic Lupus ErythematosusAutoimmune Hemolytic AnemiaMyasthenia GravisSystemic SclerosisANCA-Associated VasculitisInflammatory MyopathyIgG4-RD
- Interventions
- Biological: universal allogeneic anti-CD19/BCMA CAR T-cells
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06978738
- Locations
- 🇨🇳
Changzhou No.2 People's Hospital, Changzhou, China
Effectiveness of Multimedia Health Education to Reduce Anxiety in Patients With Vitreous Floaters
Not Applicable
Recruiting
- Conditions
- Vitreous FloatersAnxiety
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06964867
- Locations
- 🇨🇳
the Second People's Hospital of Changzhou, Changzhou, Jiangsu, China
Effectiveness and Safety of 25-Gauge Needle-Assisted Phacoemulsification of Dislocated Intravitreal Lens Nucleus
Completed
- Conditions
- Dislocated LensPars Plana VitrectomyPhacoemulsificationNeedle
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT06709378
- Locations
- 🇨🇳
the Second People's Hospital of Changzhou, Changzhou, Jiangsu, China
γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT06404281
- Locations
- 🇨🇳
Changzhou No.2, Changzhou, China
FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer
Phase 2
Recruiting
- Conditions
- Gastric Cancer
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 198
- Registration Number
- NCT06405113
- Locations
- 🇨🇳
Changzhou No.2 People's Hospital, Changzhou, China
- Prev
- 1
- 2
- Next
News
No news found